Inari Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) is set to present at the 40^th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:00 p.m. Eastern Time. The presentation will focus on the company's innovative products designed for treating venous diseases, emphasizing its minimally-invasive catheter-based mechanical thrombectomy devices. These devices, the ClotTriever and FlowTriever systems, are FDA-cleared and CE-marked for the removal of clots from peripheral blood vessels, specifically targeting conditions like deep vein thrombosis and pulmonary embolism.

IRVINE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time.

A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company focused on developing innovative products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

When will Inari Medical present at the J.P. Morgan Healthcare Conference?

Inari Medical will present on January 12, 2022, at 3:00 p.m. Eastern Time.

What products does Inari Medical focus on developing?

Inari Medical develops innovative products to treat venous diseases, including the ClotTriever and FlowTriever systems.

What conditions do the ClotTriever and FlowTriever systems target?

These systems target deep vein thrombosis and pulmonary embolism.

Are the ClotTriever and FlowTriever systems FDA-approved?

Yes, both systems are 510(k)-cleared by the FDA.

Where can I access the webcast of Inari Medical's presentation?

The webcast can be accessed on the Investor Relations section of Inari Medical's website for 30 days after the presentation.